At a glance
ClinicalIndex Comparison RecordN/ACompleted· 146 enrolled
Drug / intervention
Paradigm 722 sensor augmented pump +1 moredevice
Likely dose
Paradigm 722 sensor-augmented pump (dose adjusted per individual protocol)AI-extracted
Key inclusion· 4
- ✓Age 12 to 80 years
- ✓Type 1 Diabetes Mellitus diagnosed at least 1 year prior
- ✓Currently using insulin infusion pump for minimum 6 months
- ✓Performing at least 4 blood glucose tests per day
Key exclusion· 2
- ✕Pregnant or planning pregnancy
- ✕Unresolved tape allergy or skin conditions that would preclude sensor use
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Use of the Paradigm 722 System to Improve Glycemic Control in Adult and Adolescent Subjects With Type 1 Diabetes: A Multi-center, Randomized Controlled Trial
In Brief
A clinical study evaluating Paradigm 722 sensor augmented pump and Paradigm 715 insulin pump for Type 1 Diabetes. Completed, enrolled 146 participants across 7 sites.
Detailed Summary
The purpose of this study is to determine whether Type 1 Diabetic subjects using the Paradigm 722 System, which is a glucose sensor-augmented insulin pump, can improve glycemic control when compared to subjects using the Paradigm 715 insulin pump only.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2005
First PostedSep 2005
Primary CompletionAug 2006
Study CompletionFeb 2007
TodayJul 2026
First PostedSep 21, 2005
Enrollment StartJun 1, 2005
Primary CompletionAug 1, 2006
Study CompletionFeb 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 20.8 years ago
Interventions
Paradigm 722 sensor augmented pumpdevice
Subjects use the Paradigm 722 sensor augmented pump
Paradigm 715 insulin pumpdevice
Subjects use the Paradigm 715 insulin pump